|
1
|
Su SY, Huang JY, Jian ZH, Ho CC, Lung CC
and Liaw YP: Mortality of colorectal cancer in Taiwan, 1971–2010:
Temporal changes and age-period-cohort analysis. Int J Colorectal
Dis. 27:1665–1672. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Taiwan Cancer Registry. http://tcr.cph.ntu.edu.tw/main.php?Page=N1
|
|
3
|
Chiang CJ, Lo WC, Yang YW, You SL, Chen CJ
and Lai MS: Incidence and survival of adult cancer patients in
Taiwan, 2002–2012. J Formos Med Assoc. 115:1076–1088. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen TH, Chang SW, Huang CC, Wang KL, Yeh
KT, Liu CN, Lee H, Lin CC and Cheng YW: The prognostic significance
of APC gene mutation and miR-21 expression in advanced-stage
colorectal cancer. Colorectal Dis. 15:1367–1374.. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fodde R, Smits R and Clevers H: APC,
signal transduction and genetic instability in colorectal cancer.
Nat Rev Cancer. 1:55–67. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Reichard P: Ribonucleotide reductases: The
evolution of allosteric regulation. Arch Biochem Biophy.
397:149–155. 2002. View Article : Google Scholar
|
|
7
|
Tanaka H, Arakawa H, Yamaguchi T,
Shiraishi K, Fukuda S, Matsui K, Takei Y and Nakamura Y:
Ribonucleotide reductase gene involved in a p53-dependent
cell-cycle checkpoint for DNA damage. Nature. 404:42–49. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fan H, Villegas C and Wright JA:
Ribonucleotide reductase R2 component is a novel malignancy
determinant that cooperates with activated oncogenes to determine
transformation and malignant potential. Proc Natl Acad Sci USA.
93:14036–14040. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu X, Zhou B, Xue L, Shih J, Tye K, Lin
W, Qi C, Chu P, Un F, Wen W and Yen Y: Metastasis-suppressing
potential of ribonucleotide reductase small subunit p53R2 in human
cancer cells. Clin Cancer Res. 12:6337–6344. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu X, Zhang H, Lai L, Wang X, Loera S,
Xue L, He H, Zhang K, Hu S, Huang Y, et al: Ribouncleotide
reductase small subunit M2 serves as a prognostic biomarker and
predicts poor survival of colorectal cancers. Clin Sci (Lond).
124:567–578. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cerqueira NM, Pereira S, Fernandes PA and
Ramos MJ: Overview of ribonucleotide reductase inhibitors: An
appealing target in anti-tumour therapy. Curr Med Chem.
12:1283–1294. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Slack FJ and Weidhaas JB: MicroRNA in
cancer prognosis. N Engl J Med. 359:2720–2722. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ke TW, Hsu HL, Wu YH, Chen WT, Cheng YW
and Cheng CW: MicroRNA-224 suppresses colorectal cancer cell
migration by targeting Cdc42. Dis Markers. 2014:6171502014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu TP, Huang CC, Yeh KT, Ke TW, Wei PL
and Cheng YW: Down-regulation of let-7a-5p predicts lymph node
metastasis and prognosis impact on chemotherapy of colorectal
cancer. Surg Oncol. 25:429–434. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen X and Qin Z: Post-transcriptional
regulation by microRNA-21 and let-7a microRNA in paediatric
cholesteatoma. J Int Med Res. 39:2110–2118. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pfeffer SR, Yang CH and Pfeffer LM: The
role of miR-21 in cancer. Drug Dev Res. 76:270–277. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang F and Cheong JK: The renewed battle
against RAS-mutant cancers. Cell Mol Life Sci. 73:1845–1858. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rui YY, Zhang D, Zhou ZG, Wang C, Yang L,
Yu YY and Chen HN: Can K-ras Gene mutation be utilized as
prognostic biomarker for colorectal cancer patients receiving
chemotherapy? A meta-analysis and systematic review. PLoS One.
8:e779012013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Normanno N, Tejpar S, Morgillo F, De Luca
A, Van Cutsem E and Ciardiello F: Implications for KRAS status and
EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol.
6:519–527. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yoshida Y, Tsunoda T, Doi K, Tanaka Y,
Fujimoto T, Machida T, Ota T, Koyanagi M, Takashima Y, Sasazuki T,
et al: KRAS-mediated up-regulation of RRM2 expression is essential
for the proliferation of colorectal cancer cell lines. Anticancer
Res. 31:2535–2539. 2011.PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hsu NY, Wu JY, Liu X, Yen Y, Chen CY, Chou
MC, Lin CH, Lee H and Cheng YW: Expression status of ribonucleotide
reductase small subunits hRRM2/p53R2 as prognostic biomarkers in
stage i and ii non-small cell lung cancer. Anticancer Res.
31:3475–3481. 2011.PubMed/NCBI
|
|
23
|
Chen IC, Lee KH, Hsu YH, Wang WR, Chen CM
and Cheng YW: Expression pattern and clinicopathological relevance
of the indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase
protein in colorectal cancer. Dis Markers. 2016:81697242016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huang Y, Liu X, Wang YH, Yeh SD, Chen CL,
Nelson RA, Chu P, Wilson T and Yen Y: The prognostic value of
ribonucleotide reductase small subunit M2 in predicting recurrence
for prostate cancers. Urol Oncol. 32:51.e9–e19. 2014. View Article : Google Scholar
|
|
25
|
Wei CH, Gorgan TR, Elashoff DA, Hines OJ,
Farrell JJ and Donahue TR: A meta-analysis of gemcitabine
biomarkers in patients with pancreaticobiliary cancers. Pancreas.
42:1303–1310. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang L, Huang J and Jiang M: RRM2
computational phosphoprotein network construction and analysis
between no-tumor hepatitis/cirrhotic liver tissues and human
hepatocellular carcinoma (HCC). Cell Physiol Biochem. 26:303–310.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Maftouh M, Avan A, Funel N, Frampton AE,
Fiuji H, Pelliccioni S, Castellano L, Galla V, Peters GJ and
Giovannetti E: miR-211 modulates gemcitabine activity through
downregulation of ribonucleotide reductase and inhibits the
invasive behavior of pancreatic cancer cells. Nucleosides
Nucleotides Nucleic Acids. 33:384–393. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhong Z, Cao Y, Yang S and Zhang S:
Overexpression of RRM2 in gastric cancer cell promotes their
invasiveness via AKT/NF-κB signaling pathway. Pharmazie.
71:280–284. 2016.PubMed/NCBI
|
|
29
|
Fang Z, Gong C, Liu H, Zhang X, Mei L,
Song M, Qiu L, Luo S, Zhu Z, Zhang R, et al: E2F1 promote the
aggressiveness of human colorectal cancer by activating the
ribonucleotide reductase small subunit M2. Biochem Biophys Res
Commun. 464:407–415. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhou BS, Tsai P, Ker R, Tsai J, Ho R, Yu
J, Shih J and Yen Y: Overexpression of transfected human
ribonucleotide reductase M2 subunit in human cancer cells enhances
their invasive potential. Clin Exp Metastasis. 16:43–49. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Duxbury MS and Whang EE: RRM2 induces
NF-kB-dependent MMP-9 activation and enhances cellular
invasiveness. Biochem Biophys Res Commun. 354:190–196. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tiwari P, Sahay S, Pandey M, Qadri SS and
Gupta KP: Preventive effects of butyric acid, nicotinamide, calcium
glucarate alone or in combination during the 7, 12-dimethylbenz
anthracene induced mouse skin tumorigenesis via modulation of
K-Ras-PI3K-AKTpathway and associated micro RNAs. Biochimie.
121:112–122. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ren J, Li G, Ge J, Li X and Zhao Y: Is
K-ras gene mutation a prognostic factor for colorectal cancer: A
systematic review and meta-analysis. Dis Colon Rectum. 55:913–923.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bazan V, Migliavacca M, Zanna I, Tubiolo
C, Grassi N, Latteri MA, La Farina M, Albanese I, Dardanoni G,
Salerno S, et al: Specific codon 13 K-ras mutations are predictive
of clinical outcome in colorectal cancer patients, whereas codon 12
K-ras mutations are associated with mucinous histotype. Ann Oncol.
13:1438–1446. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Conlin A, Smith G, Carey FA, Wolf CR and
Steele RJ: The prognostic significance of K-ras, p53 and APC
mutations in colorectal carcinoma. Gut. 54:1283–1286. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pricolo VE, Finkelstein SD, Wu TT, Keller
G, Bakker A, Swalsky PA and Bland KI: Prognostic value of TP53 and
K-ras-2 mutational analysis in stage III carcinoma of the colon. Am
J Surg. 171:41–46. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Andersen SN, Lovig T, Breivik J, Lund E,
Gaudernack G, Meling GI and Rognum TO: K-ras mutations and
prognosis in large-bowel carcinomas. Scand J Gastroenterol.
32:62–69. 1997. View Article : Google Scholar : PubMed/NCBI
|
